Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 44Lymphoma, Mantle-Cell 22Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma 9Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Recurrence 6Neoplasms 6Lymphoma, B-Cell 5Leukemia, B-Cell 5Bronchiolitis Obliterans Syndrome 5Multiple Myeloma 3Leukemia, Lymphoid 3Hematologic Diseases 3Graft vs Host Disease 3Burkitt Lymphoma 3Melanoma 2Leukemia, Prolymphocytic 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioblastoma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1

Interventions

Rituximab 7Vemurafenib 4Cyclophosphamide 4Cladribine 4Specimen Handling 3Biopsy 3obinutuzumab 2ibrutinib 2fludarabine phosphate 2fludarabine 2binimetinib 2Diphenhydramine 2Dexamethasone 2Calcium Dobesilate 2CT-P10 2Acetaminophen 2venetoclax 1tovorafenib 1polatuzumab vedotin 1pembrolizumab 1immunotoxin HA22 1encorafenib 1dexamethasone acetate 1dexamethasone 21-phosphate 1brexucabtagene autoleucel 1auricularum 1acalabrutinib 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Hairy Cell × ibrutinib × 1 year × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡